Wang Jue, Wang Fen Wei, Lagrange Chad A, Hemstreet George P
Department of Internal Medicine, Section of Oncology-Hematology, University of Nebraska Medical Center, Omaha, NE, USA;
Rare Tumors. 2010 Sep 30;2(3):e47. doi: 10.4081/rt.2010.e47.
The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate. The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify ASCC of prostate cases between January 1973 and December 2006. Survival probabilities were estimated using the Kaplan-Meier methods and compared using the log-rank test. A total of 25 patients with adenosquamous cell carcinoma of the prostate were identified during the study period. The median age was 74 years (range 53-98). Twenty percent of study subjects presented with metastatic disease. Among those patients with known grade (n=16), 75% had poorly or undifferentiated histology. A total of 40% of study subjects received radical prostatectomy, while 24% of the patients had primary radiation therapy. The 1-, 3-, and 5-year cancer specific survival rates for the entire cohort were 55.2%, 37.8%, and 30.3%, respectively. For patients who underwent prostatectomy, the 1-, 3-, and 5-year survival rates were 78%, 78%, and 63%, respectively. For the patients who did not receive prostatectomy, the 1-year survival rates were 38.7% and none survived to three years. Adenosquamous cell carcinoma is a rare aggressive subtype of prostate cancer with poor cancer specific survival. The development of new therapeutic approaches for this aggressive tumor is urgently needed.
本研究的目的是调查前列腺腺鳞癌患者的流行病学、自然病史、治疗情况及长期生存率。利用监测、流行病学和最终结果（SEER）计划数据库来确定1973年1月至2006年12月期间的前列腺腺鳞癌病例。使用Kaplan-Meier方法估计生存概率，并使用对数秩检验进行比较。在研究期间共确定了25例前列腺腺鳞癌患者。中位年龄为74岁（范围53 - 98岁）。20%的研究对象出现转移性疾病。在已知分级的患者中（n = 16），75%的组织学表现为低分化或未分化。共有40%的研究对象接受了根治性前列腺切除术，而24%的患者接受了原发灶放射治疗。整个队列的1年、3年和5年癌症特异性生存率分别为55.2%、37.8%和30.3%。接受前列腺切除术的患者，1年、3年和5年生存率分别为78%、78%和63%。未接受前列腺切除术的患者，1年生存率为38.7%，且无患者存活至3年。腺鳞癌是前列腺癌一种罕见的侵袭性亚型，癌症特异性生存率较低。迫切需要针对这种侵袭性肿瘤开发新的治疗方法。
